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Background. Chronic lymphocytic leukaemia (CLL) currently remains incurable 
without stem cell transplantation, an option for only the minority of patients. 
Despite advances in chemotherapy, most patients relapse owing to the persistence 
of minimal residual disease (MRD). Substantial evidence has accrued to 
suggest that the tumour microenvironment is central to disease progression in 
CLL, with the bone marrow (BM) and lymph nodes (LN) acting as sanctuary 
sites for MRD. Whilst peripheral blood CLL cells are cell cycle arrested, significant 
rates of clonal proliferation occur in the BM/LN wherein acquisition of 
deleterious cytogenetic abnormalities such as 17p deletion may arise. Further, 
CLL cells co-cultured in vitro on stroma with CD154/IL-4 to give a proliferative 
signal, are chemoresistant to first line therapies. As proliferating cells require 
lipids for membrane synthesis, we hypothesise that proliferating CLL cells will 
have greater requirement for low density lipoprotein (LDL) compared to circulating 
CLL cells, and also that of normal resting lymphocytes providing a potentially 
differential cellular property to attack. Proof of concept of drug-loaded 
synthetic (s)LDL nanoparticles has been provided in glioblastoma and CML. We 
propose that drug loading into sLDL nanoparticles will allow selective targeting 
of proliferating CLL cells within the BM/LN proliferation centre, will protect 
drugs from plasma binding proteins, and will ultimately raise intracellular drug 
concentrations in the protective microenvironmental niche, to overcome 
chemoresistance. Aims. To determine (a) the extent of sLDL uptake by CLL 
cells compared to normal; and (b) whether sLDL uptake by CLL cells changes 
under proliferative conditions mimicking the proliferation centre. This will determine 
whether proliferating CLL cells have increased sLDL uptake compared 
to non-cycling CLL cells or normal B lymphocytes. Methods. sLDL uptake was 
assessed by flow cytometry, measuring the mean fluorescence intensity in the 
FITC channel owing to the stable incorporation of dioctadecyloxacarbocyanine 
(DiO) into the formulation. Internalisation was confirmed by deconvolution fluorescence 
microscopy. Primary CLL and normal donor samples were enriched 
for CD19+ B-lineage cells by magnetically activated cell sorting. Cells were cultured 
in media on tissue culture plastic or NT-L mouse fibroblasts with or without 
CD154/IL4. Lymphoid cells were stained with CellTrace VioletR to track cell 
division in response to proliferative signals (CD154/IL4 stroma). Results. HG3, 
a human lymphoblastoid cell line, avidly took up sLDL nanoparticles in a concentration 
(0-50 ng/mL cholesterol) and time (0.5-24h) dependent manner. 
Normal donor peripheral blood B-cells and CLL cells cultured on plastic did not 
actively take up sLDL but maintained their viability even in the highest concen- 
tration sLDL tested. Actively proliferating CLL cells on CD154/IL4 stroma could 
be targeted with sLDL unlike their non-cycling counterparts; interestingly even 
the minor population of cells that had remained undivided on stroma were also 
found to be sLDL positive. Summary. CLL cells can be selectively targeted by 
sLDL nanoparticles with respect to their non-cycling counterparts. We next will 
investigate the in vivo targeting of sLDL which we hypothesise, by virtue of 
their size, will home to lymphoreticular organs, sanctuary sites for CLL MRD. 
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